Lung cancer remains the leading cause of cancer-related death for both men and women worldwide, with an estimated 1.8 million deaths attributed to the disease each year. Non–small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancer cases. It is among some of the most genome-varied and -deranged of all cancers, which generates enormous challenges for both prevention and treatment strategies. Driver oncogenic mutations have been increasingly elucidated by the clinical use of multiplex next-generation sequencing. Genomic alterations — mainly amplification and mutations — in erythroblastic oncogene B (ERBB2), which is also known as human epidermal growth factor receptor 2 (HER2), have emerged as distinctive oncogenic drivers in NSCLC and are considered a novel therapeutic target for treating NSCLC.
What do you know about HER2 mutations in NSCLC? Test your knowledge with this quick quiz.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer - Medscape - Nov 23, 2021.